Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
49
GMAB Quote, Financials, Valuation and Earnings
Last price:
$22.03
Seasonality move
:
4.22%
Day range:
$21.41 - $21.89
52-week range:
$17.24 - $28.56
Dividend yield:
0%
P/E ratio:
13.00x
P/S ratio:
4.58x
P/B ratio:
2.54x
Volume:
1M
Avg. volume:
1.4M
1-year change:
-19%
Market cap:
$13.5B
Revenue:
$3B
EPS (TTM):
$1.68
Analysts' Opinion
-
Consensus RatingGenmab AS has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.50, Genmab AS has an estimated upside of 39.46% from its current price of $21.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 8.55% downside risk from its current price of $21.87.
Fair Value
-
According to the consensus of 7 analysts, Genmab AS has 39.46% upside to fair value with a price target of $30.50 per share.
GMAB vs. S&P 500
-
Over the past 5 trading days, Genmab AS has overperformed the S&P 500 by 1.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Genmab AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Genmab AS has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Genmab AS reported revenues of $715M.
Earnings Growth
-
Genmab AS has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Genmab AS reported earnings per share of $0.31.
Enterprise value:
10.2B
EV / Invested capital:
--
Price / LTM sales:
4.58x
EV / EBIT:
8.07x
EV / Revenue:
3.34x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
9.45x
Price / Operating cash flow:
12.96x
Enterprise value / EBITDA:
7.70x
Gross Profit (TTM):
$2.9B
Return On Assets:
18.18%
Net Income Margin (TTM):
35.32%
Return On Equity:
22.23%
Return On Invested Capital:
22.23%
Operating Margin:
26.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.7B | $3.1B | $603M | $715M | |
| Gross Profit | -- | $2.6B | $2.9B | $576M | $673M | |
| Operating Income | $905.4M | $853.3M | $1B | $116M | $188M | |
| EBITDA | $984.1M | $1.1B | $1.3B | $266M | $265M | |
| Diluted EPS | $1.17 | $1.24 | $1.68 | $0.29 | $0.31 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.1B | $3.5B | $4.1B | $5B | $4B | |
| Total Assets | $3.5B | $3.7B | $4.4B | $5.3B | $6.6B | |
| Current Liabilities | $203.8M | $200.9M | $286.2M | $399.1M | $756M | |
| Total Liabilities | $333.4M | $329.4M | $469M | $605.1M | $1.3B | |
| Total Equity | $3.2B | $3.4B | $4B | $4.7B | $5.3B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $948.5M | $841.2M | $1.2B | $219M | $287M | |
| Cash From Investing | -$299.2M | -$398.4M | -$1.2B | -$210M | -$43M | |
| Cash From Financing | -$193.4M | -$85.5M | -$474.8M | -$85M | -$13M | |
| Free Cash Flow | $896.2M | $796.6M | $1.1B | $215M | $257M | |
GMAB
Sector
Market Cap
$13.5B
$34.4M
Price % of 52-Week High
76.58%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
3.73%
-1.01%
1-Year Price Total Return
-19%
-37.36%
Beta (5-Year)
0.938
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$21.39
200-day SMA
Buy
Level
$21.21
Bollinger Bands (100)
Buy
Level
19.46 - 22.16
Chaikin Money Flow
Buy
Level
2.7M
20-day SMA
Buy
Level
$21.06
Relative Strength Index (RSI14)
Buy
Level
57.34
ADX Line
Buy
Level
29.21
Williams %R
Sell
Level
-1.6913
50-day SMA
Buy
Level
$21.07
MACD (12, 26)
Buy
Level
5.88
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
3.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.7063)
Buy
CA Score
(Annual)
Level (2.3195)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-5.1788)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Stock Forecast FAQ
In the current month, GMAB has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The GMAB average analyst price target in the past 3 months is $30.50.
-
Where Will Genmab AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Genmab AS share price will rise to $30.50 per share over the next 12 months.
-
What Do Analysts Say About Genmab AS?
Analysts are divided on their view about Genmab AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Genmab AS is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Genmab AS's Price Target?
The price target for Genmab AS over the next 1-year time period is forecast to be $30.50 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is GMAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Genmab AS is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GMAB?
You can purchase shares of Genmab AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Genmab AS shares.
-
What Is The Genmab AS Share Price Today?
Genmab AS was last trading at $22.03 per share. This represents the most recent stock quote for Genmab AS. Yesterday, Genmab AS closed at $21.87 per share.
-
How To Buy Genmab AS Stock Online?
In order to purchase Genmab AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
